Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$39.25 USD
-1.50 (-3.68%)
Updated May 31, 2024 04:00 PM ET
After-Market: $39.25 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Apellis Pharmaceuticals, Inc. [APLS]
Reports for Purchase
Showing records 261 - 280 ( 285 total )
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PEGASUS Makes EHA Debut; Regulatory Filings Next Step
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pegcetacoplan Filing On Track For 2H20 After FDA Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Note Offering Necessary To Extend Cash Runway
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Steady As She Goes; Largely Uneventful 1Q20 Report Ahead Of Mid-Year Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Upgrade to Neutral; Despite Some Data Questions, Valuation Warrants Revisiting
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ahead of Detailed Data, FDA Feedback - Uneventful 4Q19 EPS Report
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
APLS Prices Secondary Offering - Extends Cash Runway
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L